These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 28554411)

  • 1. Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease.
    Johar I; Mollenhauer B; Aarsland D
    Int Rev Neurobiol; 2017; 132():275-294. PubMed ID: 28554411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
    Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
    J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
    Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
    J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of cerebrospinal fluid Aβ
    Hu X; Yang Y; Gong D
    Neurol Sci; 2017 Nov; 38(11):1953-1961. PubMed ID: 28808876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients.
    Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A
    CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olfactory impairment predicts cognitive decline in early Parkinson's disease.
    Fullard ME; Tran B; Xie SX; Toledo JB; Scordia C; Linder C; Purri R; Weintraub D; Duda JE; Chahine LM; Morley JF
    Parkinsonism Relat Disord; 2016 Apr; 25():45-51. PubMed ID: 26923521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
    Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
    J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease.
    Parnetti L; Farotti L; Eusebi P; Chiasserini D; De Carlo C; Giannandrea D; Salvadori N; Lisetti V; Tambasco N; Rossi A; Majbour NK; El-Agnaf O; Calabresi P
    Front Aging Neurosci; 2014; 6():53. PubMed ID: 24744728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.
    Wilson EN; Swarovski MS; Linortner P; Shahid M; Zuckerman AJ; Wang Q; Channappa D; Minhas PS; Mhatre SD; Plowey ED; Quinn JF; Zabetian CP; Tian L; Longo FM; Cholerton B; Montine TJ; Poston KL; Andreasson KI
    Brain; 2020 Mar; 143(3):932-943. PubMed ID: 32065223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's and Lewy body dementia CSF biomarkers.
    Parnetti L; Paciotti S; Farotti L; Bellomo G; Sepe FN; Eusebi P
    Clin Chim Acta; 2019 Aug; 495():318-325. PubMed ID: 31051162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline concentration of misfolded α-synuclein aggregates in cerebrospinal fluid predicts risk of cognitive decline in Parkinson's disease.
    Ning H; Wu Q; Han D; Yao T; Wang J; Lu W; Lv S; Jia Q; Li X
    Neuropathol Appl Neurobiol; 2019 Jun; 45(4):398-409. PubMed ID: 30346044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease.
    Førland MG; Öhrfelt A; Dalen I; Tysnes OB; Blennow K; Zetterberg H; Pedersen KF; Alves G; Lange J
    Parkinsonism Relat Disord; 2018 Apr; 49():4-8. PubMed ID: 29409704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of CSF α-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.
    García-Ayllón MS; Monge-Argilés JA; Monge-García V; Navarrete F; Cortés-Gómez MA; Sánchez-Payá J; Manzanares J; Gasparini-Berenguer R; Leiva-Santana C; Sáez-Valero J
    J Neurochem; 2019 Jul; 150(2):218-230. PubMed ID: 31077373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease.
    van der Zee S; Vermeiren Y; Fransen E; Van Dam D; Aerts T; Gerritsen MJ; Spikman JM; van Laar T; De Deyn PP
    J Parkinsons Dis; 2018; 8(1):71-84. PubMed ID: 29480224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.
    Bäckström DC; Eriksson Domellöf M; Linder J; Olsson B; Öhrfelt A; Trupp M; Zetterberg H; Blennow K; Forsgren L
    JAMA Neurol; 2015 Oct; 72(10):1175-82. PubMed ID: 26258692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.
    Leaver K; Poston KL
    Neuropsychol Rev; 2015 Dec; 25(4):411-23. PubMed ID: 26626621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.